Use of the tumor necrosis factor-blockers for Crohn's disease

Table 14 Therapeutic gain of infliximab for Crohn's disease maintenance of response and remission (%)

Assessment week	Treatment	IFX (mg/kg)			PL	Therapeutic gain
		5	10	20
Remission	0, 2, 6 wk
12		751	-	-	38	371
24		571	-	-	29	281
52		401	-	-	22	181
Response	2, 6, 8 wk
30		501	581	-	27	23-311
54		371	471	-	15	22-321
Remission	2, 6, 8 wk
30		391	39	-	21	181-18
54		281	38	-	14	141-24
Response	q8 wk
54	until week 54	361	-	-	6	301
Response	q8 wk (4 infusions)
36		-	721	-	44	281
44			621	-	37	251
Remission	q8 wk (4 infusions)	-
12		-	141		44	-301
36			601		35	251
44			531		20	331

¹Significant difference. PL: Placebo; IFX: Infliximab.